International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2004
Clinical TrialPredictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.
To evaluate possible clinical and dosimetric predictors of acute esophagitis in patients with locally advanced non-small-cell lung carcinoma treated in a prospective Phase I-II trimodality protocol. ⋯ In patients undergoing concurrent high-dose chemotherapy and hyperfractionated radiotherapy, a low pretherapy body mass index and percentage of esophagus volume treated to >50 Gy were significantly associated with acute Grade 2 or worse esophagitis.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2004
Impact of radiation oncology practice on pain: a cross-sectional survey.
A cross-sectional study was performed to evaluate the prevalence of pain in our radiotherapy (RT) department. The impact of RT practice on pain and pain management were analyzed. ⋯ The prevalence of pain was high in the department. The specific practice of RT worsened pain and nearly one-half of patients were not satisfied with its management. The necessity for medical staff to be more available was highlighted by patients.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2004
Comparative StudyDose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions.
This study evaluates photon beam intensity-modulated stereotactic radiotherapy (IMSRT) based on dynamic leaf motion of a micromultileaf collimator (mMLC), proton beams, and intensity-modulated proton therapy (IMPT) with respect to target coverage and organs at risk. ⋯ The addition of intensity modulation improves the conformality of mMLC-based SCRT. Conformation of dose to the PTV is comparable for IMSRT, protons, and IMPT. Concerning the sparing of OAR, IMSRT is equivalent to IMPT, and IMPT is superior to conventional protons. The advantage of protons lies in the lower integral dose.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2004
Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer.
Hypofractionated stereotactic radiotherapy (SRT) for Stage I non-small-cell lung cancer requires that meticulous attention be paid toward ensuring optimal target definition. Two computed tomography (CT) scan techniques for defining internal target volumes (ITV) were evaluated. ⋯ Individualized ITVs can improve target definition for SRT of Stage I non-small-cell lung cancer, and use of only a single CT scan with a 10-mm margin is inappropriate. A single 4D scan generates comparable or larger ITVs than are generated using six unmonitored rapid CT scans, a finding related to the ability to account for all respiration-correlated mobility.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2004
Do differences in target volume definition in prostate cancer lead to clinically relevant differences in normal tissue toxicity?
Many studies have described the quantitated differences between clinicians in target volume definition in prostate cancer. However, few studies have looked at the clinical effects of this. We aimed to assess the relevance and sequelae of such differences. ⋯ The statistically significant difference in outlined volumes of the CTV1, CTV2, and PTV1 among the 5 clinicians is in keeping with the findings of previous studies. However, the interclinician variability did not result in clinically relevant outcomes with respect to the irradiated volume of rectum and bladder or NTCP. This may have been because the outlined areas in which interclinician differences were smallest (the rectal-prostate and prostate-bladder interfaces) are the areas that have the greatest effect on normal tissue toxicity. For the areas in which the interclinician correlation was lowest (the prostatic apex and distal seminal vesicles), the effects on normal tissue toxicity are smallest. The results of this study suggest that interclinician outlining differences in prostate cancer may have less clinical relevance than was previously thought.